- Tytuł:
- First-line durvalumab in patients with PD-L1 positive, advanced non-small cell lung cancer (NSCLC) with a performance status of 2 (PS2). Primary analysis of the multicenter, single-arm phase II trial SAKK 19/17
- Autorzy:
- Źródło:
- In European Journal of Cancer March 2024 200
Czasopismo naukowe